Therapies and Protocols Library
Every article, presentation, spotlight, and news item we've tagged to Therapies and Protocols.
Showing 73–79 of 79
Automated brain volumetry gains EU clearance for longevity tracking
Cortechs.ai obtained expanded EU medical device certification for its NeuroQuant platform, enabling automated quantitative imaging across neurology, neuro-oncology, and prostate analysis. The certification validates a scalable framework for AI-driven tissue volumetry and longitudinal tracking in clinical practice across the European Economic Area.
Ribo, Insilico partner to accelerate siRNA drug development using AI
Ribo and Insilico Medicine are collaborating to accelerate siRNA drug development by combining siRNA capabilities with AI-powered target discovery and molecule design. siRNA therapeutics can selectively silence disease-causing genes with rapid development timelines and extended therapeutic duration.
Macrophage Reprogramming via LNP-mRNA Targets Fibrotic Disease
Resolution Therapeutics is systematically evaluating lipid nanoparticle delivery systems paired with mRNA payloads designed to reprogram myeloid cells toward anti-inflammatory phenotypes. This dual-platform approach—combining in vivo LNP optimization with their Phase 1/2 autologous regenerative macrophage therapy—targets a fundamental driver of age-related disease: chronic inflammatory fibrosis.
Correction to “Photobiomodulation Suppresses JNK3 by Activation of ERK/MKP7 to Attenuate AMPA Receptor Endocytosis in Alzheimer's Disease”
A correction to prior research on photobiomodulation's mechanism in Alzheimer's disease clarifies the molecular pathway by which light exposure modulates neuroinflammatory signaling. The finding reinforces the relevance of non-pharmacological interventions targeting neurodegeneration at the cellular level.
Ultrasound Gene Delivery Solves Repeat Treatment Problem
SonoThera's ultrasound-based gene delivery platform addresses a fundamental constraint in genetic medicine: the inability to repeat treatments and the size limitations of viral vectors. The technology uses microbubbles and targeted ultrasound to open cellular pathways without immune recognition, potentially enabling the repeated interventions required for aging-related therapies.
NeuroTherapia clears Phase 2a in novel Alzheimer’s treatment
NeuroTherapia's oral Alzheimer's candidate NTRX-07 completed Phase 2a with safety clearance and early signals suggesting effects on neuroinflammation, the chronic immune dysregulation increasingly recognized as a major driver of cognitive decline. The drug targets brain inflammation rather than amyloid alone, representing a shift toward multi-system disease understanding.
NK Cell Therapy Targets Neurodegeneration Beyond Alzheimer's
NkGen Biotech will present Troculeucel, a cryopreserved autologous NK cell therapy, at BIOCHINA 2026, with Phase 2 trials underway for Alzheimer's disease and potential expansion into ALS, frontotemporal dementia, and Parkinson's disease. The therapy represents a cell-based approach to neurodegenerative conditions where conventional pharmacology has shown limited efficacy.